Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
This study is ongoing, but not recruiting participants.
Study NCT00416819 Information provided by University of California, San Francisco
First Received on December 27, 2006. Last Updated on October 1, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Additional conditions recognized in this trial
Central Nervous System Neoplasms
Nervous System Neoplasms
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Nervous System Diseases
Interventions listed in this trial
filgrastim
rituximab
cytarabine
etoposide phosphate
leucovorin calcium
methotrexate
temozolomide
Additional drug interventions recognized in this trial
Calcium, Dietary
Etoposide
Lenograstim
Leucovorin
Levoleucovorin
More general drug interventions related to this trial
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Adjuvants, Immunologic
Alkylating Agents
Anti-Infective Agents
Antidotes
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Antiviral Agents
Bone Density Conservation Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Reproductive Control Agents
Therapeutic Uses
Vitamin B Complex
Vitamins
Sponsors listed in this trial
University of California, San Francisco
National Cancer Institute (NCI)
Back to top of Main Content
